No Cover Image

Journal article 572 views

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

Steve Bain Orcid Logo, Thinzar Min

The Lancet, Volume: 402, Issue: 10401

Swansea University Authors: Steve Bain Orcid Logo, Thinzar Min

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1016/s0140-6736(23)01182-0

Published in: The Lancet
ISSN: 0140-6736
Published: Elsevier BV 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63790
first_indexed 2023-07-06T13:00:05Z
last_indexed 2024-11-25T14:12:56Z
id cronfa63790
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2023-09-04T15:34:32.8331267</datestamp><bib-version>v2</bib-version><id>63790</id><entry>2023-07-06</entry><title>A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>27cba511a4800fefddb6885ffffdb8b2</sid><firstname>Thinzar</firstname><surname>Min</surname><name>Thinzar Min</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2023-07-06</date><deptcode>MEDS</deptcode><abstract/><type>Journal Article</type><journal>The Lancet</journal><volume>402</volume><journalNumber>10401</journalNumber><paginationStart/><paginationEnd/><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0140-6736</issnPrint><issnElectronic/><keywords/><publishedDay>12</publishedDay><publishedMonth>8</publishedMonth><publishedYear>2023</publishedYear><publishedDate>2023-08-12</publishedDate><doi>10.1016/s0140-6736(23)01182-0</doi><url>http://dx.doi.org/10.1016/s0140-6736(23)01182-0</url><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2023-09-04T15:34:32.8331267</lastEdited><Created>2023-07-06T13:58:01.2149939</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medical Physics</level></path><authors><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>1</order></author><author><firstname>Thinzar</firstname><surname>Min</surname><order>2</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2023-09-04T15:34:32.8331267 v2 63790 2023-07-06 A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 27cba511a4800fefddb6885ffffdb8b2 Thinzar Min Thinzar Min true false 2023-07-06 MEDS Journal Article The Lancet 402 10401 Elsevier BV 0140-6736 12 8 2023 2023-08-12 10.1016/s0140-6736(23)01182-0 http://dx.doi.org/10.1016/s0140-6736(23)01182-0 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2023-09-04T15:34:32.8331267 2023-07-06T13:58:01.2149939 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medical Physics Steve Bain 0000-0001-8519-4964 1 Thinzar Min 2
title A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
spellingShingle A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
Steve Bain
Thinzar Min
title_short A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
title_full A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
title_fullStr A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
title_full_unstemmed A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
title_sort A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
27cba511a4800fefddb6885ffffdb8b2
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
27cba511a4800fefddb6885ffffdb8b2_***_Thinzar Min
author Steve Bain
Thinzar Min
author2 Steve Bain
Thinzar Min
format Journal article
container_title The Lancet
container_volume 402
container_issue 10401
publishDate 2023
institution Swansea University
issn 0140-6736
doi_str_mv 10.1016/s0140-6736(23)01182-0
publisher Elsevier BV
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medical Physics{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medical Physics
url http://dx.doi.org/10.1016/s0140-6736(23)01182-0
document_store_str 0
active_str 0
published_date 2023-08-12T20:32:09Z
_version_ 1821982515173261312
score 11.048042

Similar Items